BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11139324)

  • 1. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites.
    Rapakko K; Allinen M; Syrjäkoski K; Vahteristo P; Huusko P; Vähäkangas K; Eerola H; Kainu T; Kallioniemi OP; Nevanlinna H; Winqvist R
    Br J Cancer; 2001 Jan; 84(1):116-9. PubMed ID: 11139324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
    Güran S; Ozet A; Dede M; Gille JJ; Yenen MC
    Cancer Genet Cytogenet; 2005 Jul; 160(2):164-8. PubMed ID: 15993273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
    Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
    Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
    Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
    Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three germline mutations in the TP53 gene.
    Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
    Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
    Allinen M; Huusko P; Mäntyniemi S; Launonen V; Winqvist R
    Br J Cancer; 2001 Jul; 85(2):209-12. PubMed ID: 11461078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
    Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
    Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
    Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
    Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
    Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
    Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.
    Krutilkova V; Trkova M; Fleitz J; Gregor V; Novotna K; Krepelova A; Sumerauer D; Kodet R; Siruckova S; Plevova P; Bendova S; Hedvicakova P; Foreman NK; Sedlacek Z
    Eur J Cancer; 2005 Jul; 41(11):1597-603. PubMed ID: 15925506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
    Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary mutations in the p53 tumor suppressor gene; significance for clinical practice. National Work Group Hereditary Mamma Carcinoma].
    Menko FH; Nooy MA; Vasen HF
    Ned Tijdschr Geneeskd; 1996 Jun; 140(26):1347-50. PubMed ID: 8710022
    [No Abstract]   [Full Text] [Related]  

  • 17. Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation.
    Janavičius R; Andrėkutė K; Mickys U; Rudaitis V; Brasiūnienė B; Griškevičius L
    Breast J; 2011; 17(4):409-15. PubMed ID: 21535297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of germline TP53 splicing mutations and their genetic and functional analysis.
    Varley JM; Attwooll C; White G; McGown G; Thorncroft M; Kelsey AM; Greaves M; Boyle J; Birch JM
    Oncogene; 2001 May; 20(21):2647-54. PubMed ID: 11420676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
    Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.